Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden flag Sweden · Delayed Price · Currency is SEK
17.18
-0.28 (-1.60%)
At close: Aug 1, 2025

Cinclus Pharma Holding AB Company Description

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China.

The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease.

It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H.

pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

Cinclus Pharma Holding AB (publ)
CountrySweden
Founded2014
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees18
CEOChrister Ahlberg

Contact Details

Address:
Kungsbron 1
Stockholm, 11122
Sweden
Phone46 8 13 33 10
Websitecincluspharma.com

Stock Details

Ticker SymbolCINPHA
ExchangeNasdaq Stockholm
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0020388577
SIC Code2834

Key Executives

NamePosition
Christer AhlbergChief Executive Officer and President
Dr. Lennart Hansson Ph.D.Co-founder and Chairman of the Board
Peter UngeCo-founder and Director
Maria EngstromChief Financial Officer
Jesper WiklundDirector of Corporate and Business Development
Kajsa LarssonChief Medical Officer